The adhesion molecule and cytokine profile of multiple sclerosis lesions

Annals of Neurology

Volumn 37, Issue 4, 1995, Pages 424-435

  Cannella, Barbara ^a,b   Raine, Cedric S ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b New York State Office of Mental Retardation and Developmental Disabilities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CELL ADHESION MOLECULE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; TISSUE DISTRIBUTION;

ADULT; AGED; CELL ADHESION MOLECULES; CYTOKINES; FEMALE; HUMAN; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGE; MULTIPLE SCLEROSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0028941871     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410370404     Document Type: Article

References (64)

1. Raine CS. Demyelinating diseases
2. Immune cell traffic control and the central nervous system
3. The role of cytokines in inflammatory conditions of the central nervous system
4. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS
5. VCAM‐1 on activated endothelium with the leukocyte integrin VLA‐4 at a site distinct from the VLA‐4/fibronectin binding site
6. A human intercellular adhesion molecule (ICAM‐1) distinct from LFA‐1
7. Purified intercellular adhesion molecule‐1 (ICAM‐1) is a ligand for lymphocyte function‐associated antigen‐1 (LFA‐1)
8. Adhesion receptors of the immune system
9. Intercellular adhesion molecule‐1 (ICAM‐1) in cellular immune reactions in the human central nervous system
10. Adhesion molecules and central nervous system inflammation
11. Expression of leucocyte adhesion molecules at the human blood brain barrier (BBB)
12. Microglial changes in multiple sclerosis lesions
13. Expression of vascular cell adhesion molecule‐1 in inflammatory disorders of the central nervous system
14. The VLA‐4/VCAM‐1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium
15. Immunoregulatory molecules and IL2 receptors identified in multiple sclerosis brain
16. Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis
17. Interferon‐γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions
18. Tumor necrosis factor identified in multiple sclerosis brain
19. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
20. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotrophic virus
21. Tumor necrosis factor alpha production by astrocytes; induction of lipopolysaccharide, IFN‐gamma, IL‐1 beta
22. Differential expression of transforming growth factor‐β1, β2, and β3 by glioblastoma cells, astrocytes and microglia
23. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL‐1β
24. Regulation of intercellular molecule‐1 gene expression by tumor necrosis factor‐α, interleukin‐1β, and interferon‐γ in astrocytes
25. T cell receptor Vα‐Vβ repertoire and cytokine gene expression in active multiple sclerosis lesions
26. Intercrines in brain pathology. Expression of intercrines in a multiple sclerosis and Morbus Creutzfeld‐Jakob lesion
27. Cytokine in RNA expression in inflammatory multiple sclerosis lesions: detection by non‐radioactive in situ hybridization
28. Th1 and Th2 cells; different patterns of lymphokine secretion lead to different functional properties
29. Overlapping patterns of activation of human endothelial cells by interleukin‐1, tumor necrosis factor and immune interferon
30. Induction by IL 1 and interferon γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM‐1)
31. + T cell infiltration
32. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm
33. Vascular and nonvascular expression of INCAM‐110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissue
34. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis
35. Lymphocyte function associated antigen‐1 (LFA‐1) interaction with intercellular adhesion molecule‐1 (ICAM‐1) is one of at least 3 mechanisms for lymphoctye adhesion to cultured endothelial cells
36. Identification of surface proteins mediating adherence of CD11/CD18‐deficient lymphoblastoid cells to cultured endothelium
37. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin
38. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM‐1
39. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma
40. Anti‐adhesion molecule therapy in experimental autoimmune encephalomyelitis
41. Augmentation of adoptively‐transferred experimental allergic encephalomylitis by administration of a monoclonal antibody specific for LFA‐1α
42. ICAM‐1 dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine‐induced inflammation of the central nervous system
43. Antigen‐presenting function of the macrophage
44. Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope‐specific T‐cell line
45. Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination
46. Superantigen modulation of experimental allergic encephalomyelitis: activation or anergy determines outcome
47. Modulation of cytokine production by transforming growth factor‐β
48. H2 responses
49. Interleukin‐10 (IL10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL10 by monocytes
50. Lymphocyte responses and cytokines
51. Lymphokines and immunoregulatory molecules in subacute sclerosing panencephalitis
52. IL10 ingibits cytokine production by activated macrophages
53. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL‐10 mRNA expression correlates with recovery
54. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth
55. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor‐β1
56. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor‐β1
57. Proteoglycans on endothelial cells present adhesion‐inducing cytokines to leukocytes
58. Cytokine‐induced immune deviation as a therapy for inflammatory autoimmune disease
59. An antibody to lymphotoxin and tumor necrosis factor prevents experimental allergic encephalomyelitis
60. Anti‐cytokine therapy abrogates autoimmune demyelination
61. Vascular cell adhesion molecule‐1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis
62. Experimental autoimmune encephalomyelitis is exacerbated by IL‐1α and suppressed by soluble IL‐1 receptors
63. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions
64. Correlation between MRI findings and lesion development in chronic active multiple sclerosis